Safety and efficacy of peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTA⁰-Tyr³-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors.

ABSTRACT:

Purpose

Peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu-DOTA⁰-Tyr³-octreotate (¹⁷⁷Lu-DOTATATE) is one of the most reliable treatments for unresectable, progressive neuroendocrine tumors (NETs) with somatostatin receptor expression. We have, for the first time, reported the results of the tolerability, safety, pharmacokinetics, dosimetry, and efficacy of this treatment for Japanese patients with NET.

Methods

Patients with unresectable, somatostatin receptor scintigraphy (SRS)-positive NETs were enrolled in this phase I clinical trial. They were treated with 29.6 GBq of ¹⁷⁷Lu-DOTATATE (four doses of 7.4 GBq) combined with amino acid solution infusion plus octreotide long-acting release (LAR) 30 mg. The primary obje

SUBMITTER: Kobayashi N 

PROVIDER: S-EPMC8557155 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature